SEBI rejects plea of Danny Gaekwad for Religare open offer

The Securities and Exchange Board of India (SEBI) on Tuesday returned Florida-based businessman Digvijay (Danny) Gaekwad’s letter seeking permission to make a competing open offer for acquiring shares in Religare Enterprises (REL).

In an exchange notification, REL shared SEBI’s response to Gaekwad’s proposal to acquire a 55% stake at Rs 275 per share — a premium of 17% over Burmans-led entities’ offer of Rs 235 a share.

Also ReadDLF’s ultra-luxury bet pays off? Nuvama says…

“The letters submitted by Digvijay Laxmansinh Gaekwad are being returned since the same is not an exemption application in terms of Regulation 11 of SEBI (SAST) Regulations, 2011,” the regulator said. On January 26, REL had outlined Gaekwad’s intent in a stock exchange filing.  

It will be interesting to see if Gaekwad approaches the Securities Appellate Tribunal to challenge the SEBI decision. Shares of Religare Enterprises closed down 3.7% at Rs 243.05 on the BSE on Tuesday.

Speaking to media after the offer was declared, Gaekwad said his offer was not ‘out of the blue’ and he believed that the company was undervalued. He added that his attorneys and merchant bankers had begun the due diligence process and he had communicated to SEBI about his intentions. However, SEBI’s response indicates that the letter did not meet the application criteria under the SEBI SAST Regulations.

Gaekwad’s letter had stated that the Burmans’ open offer price of Rs 235 per share “grossly undervalues” the real worth of REL and is detrimental to public shareholders – a position that independent directors of REL had taken earlier.

The Burmans had objected to Gaekwad’s letter, saying that the competing offer should have been made within 15 days from the date of the public statement, which was October 4, 2023. Gaekwad’s offer came after almost 400 days.

The Burmans also argued that the letter lacked substance and bona fides, offered no indication of any source of funds, and was intended to mislead public shareholders of REL.

Also ReadMotilal Oswal reiterates ‘Buy’ on Coal India. Here are 3 reasons why…

Last week, in a notification to the exchanges, REL said a minority shareholder had approached the Delhi High Court, and was seeking to stop Burmans’ open offer bid.

 » Read More

Related Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

Range bound session: Nifty ends above 23,600, Sensex holds 78,000 led by Adani Ports, Infosys

The stock markets faced a downturn on Thursday, with major indices closing in the red. The BSE Sensex dropped by 213.12 points or 0.27%, ending the day at 78,058.16, while the NSE Nifty 50 saw a decline of 70.15 points, down by 0.3%, and closed at 23,626.15. The Nifty Bank index also ended the day

IT stocks stable as Cognizant raises annual and quarterly revenue guidance

Shares of Indian IT companies are in the spotlight today after the Nasdaq-listed IT services major Cognizant Technology Solutions, reported its Q4 results that exceeded Wall Street expectations. The Nifty IT Index as well as individual tech counters like Infosys, Wipro, Tech Mahindra and HCL Tech are all in the green even as the markets